Questions / meals, weight and strength
What answers can help with your treatment questions?
Smaller meals can leave you hungry. These answers explain what treating people has shown, what happened only in animals, and where safety remains uncertain.
Can you judge a tirzepatide product by its name?
Tirzepatide has a 39-amino-acid chain; these amino acids also form proteins when joined together. The copied gut hormones, GIP and GLP-1, affect blood sugar. A blood protein holds the drug longer [2]. Approval checks concern the particular medicine, its manufacture and human trials. You can't judge another product's contents or approval from the name alone.
Why can't tirzepatide cell tests predict your appetite?
Cells in a dish don't show how hungry you feel. Tirzepatide increases sugar-lowering insulin, reduces sugar-raising glucagon and slows stomach emptying. Appetite also falls. Laboratory tests found different cell responses to each gut-hormone action [6]. Those tests can't establish which response mattered most for hunger or predict another drug's effects.
How did the placebo weight result compare with tirzepatide?
Your weight loss could differ from the group averages. At 72 weeks, average changes ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% for placebo [4]. The medicine being tested was absent from the placebo treatment. Each minus sign means lost weight, with larger average losses from tirzepatide.
What does semaglutide do around mealtimes?
Semaglutide copies GLP-1, a gut hormone affecting appetite and sugar; natural GLP-1 disappears faster. High blood sugar prompts release of insulin, which the drug helps increase. Semaglutide reduces sugar-raising glucagon. Food leaves the stomach slower, and hunger eases. Human trials looked for unwanted effects and checked weight along with serious trouble affecting hearts or kidneys [8][9][10][11]. They don't predict your result.
How much weight changed in the semaglutide trial?
The trial average cannot promise how much weight you would lose. Semaglutide copies the GLP-1 gut hormone to affect appetite. In STEP 1, average changes after 68 weeks were -14.9% with semaglutide and -2.4% with placebo [10]. Placebo contained no semaglutide. The minus signs describe weight lost, with more average loss from semaglutide.
Which drug gave more average loss in the direct trial?
People with diabetes were excluded, so the finding has limits for your health question. The 751 adults had obesity and no type 2 diabetes. Average weight changes after 72 weeks were -20.2% with tirzepatide and -13.7% with semaglutide [1]. Tirzepatide produced more average loss, without settling every other health question.
Was AOD-9604 designed to cause the growth effects of growth hormone?
AOD-9604 has a 16-amino-acid chain; proteins also contain these parts joined together. Researchers used growth hormone's far end to target fat while avoiding effects on growth. The substance differs from whole growth hormone, and human treatment with the substance hasn't received approval. Benefit for you remains unproved.
Did AOD-9604 show worthwhile weight loss in people?
The encouraging fat and weight changes came from mice [15][16]. Human testing failed to establish useful weight loss. Side effects were similar with treatment and with placebo containing none of the substance [14]. You can't take few complaints during a short test as proof of lasting safety or worthwhile benefit.
Do the AOD-9604 knee findings apply to your arthritis?
The knee study treated rabbits, leaving help for your arthritis unproved. Mouse tests found less new fat and more fat burning [15][16]. Treated rabbits had less knee-cartilage damage [12]. Cartilage covers bone ends with a smooth surface so joints move easily. These animal results don't establish human weight or arthritis benefit.
What happened to MOTS-c mice whose movement was restricted?
These experiments didn't establish human strength benefit. Mice given MOTS-c lost less muscle while unable to move freely. More sugar passed into the treated muscles. In further tests, treated mice improved their grip, running or walking [17][19][20][21]. The results suggest further questions, but cannot promise that extra treatment will keep you strong.
What can the MOTS-c blood study tell you about harm?
Nobody received extra MOTS-c in the study that measured people's natural blood levels [18]. That study can't show treatment side effects. These papers contain no completed human treatment safety trial. Your body making the substance already doesn't establish that extra amounts would be harmless.
Is there a proved safe human treatment plan for MOTS-c?
FDA hasn't approved human treatment with MOTS-c, and these papers don't provide a proved safe treatment plan. How added MOTS-c enters human blood and leaves the body remains untested here. Animal treatment amounts can't establish safe amounts for you. We give no instructions for treating people.